Recent Updates
Recently added Catalysts
BIIB

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia

Monday, March 3, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia
Price reaction · baseline $140.5 (2025-02-28 close) · clean, no other BIIB news in the window
day 0 close · peak
+0.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis

Full Press Release Details

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia.
ShareAdd on Google
Tags: BIIB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 3, 2025

Biotech snapshot

Cash runway
$3878M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AlefaceptPhase 3
Chronic Plaque Psoriasis →

Catalyst track record

+34%
best trade around BIIB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BIIB.

See every catalyst's timing & PoA →